The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug
Open accessAbstract
OBJECTIVES: Infection with yellow fever virus (YFV), the prototypic mosquito-borne flavivirus, causes severe febrile disease with haemorrhage, multi-organ failure and a high mortality. Moreover, in recent years the Flavivirus genus has gained further attention due to re-emergence and increasing incidence of West Nile, dengue and Japanese encephalitis viruses. Potent and safe antivirals are urgently needed. METHODS: Starting from the crystal structure of the NS3 helicase from Kunjin virus (an Australian variant of West Nile virus), we identified a novel, unexploited protein site that might be involved in the helicase catalytic cycle and could thus in principle be targeted for enzyme inhibition. In silico docking of a library of small molecules allowed us to identify a few selected compounds with high predicted affinity for the new site. Their activity against helicases from several flaviviruses was confirmed in in vitro helicase/enzymatic assays. The effect on the in vitro replication of flaviviruses was then evaluated. RESULTS: Ivermectin, a broadly used anti-helminthic drug, proved to be a highly potent inhibitor of YFV replication (EC₅₀ values in the sub-nanomolar range). Moreover, ivermectin inhibited, although less efficiently, the replication of several other flaviviruses, i.e. dengue fever, Japanese encephalitis and tick-borne encephalitis viruses. Ivermectin exerts its effect at a timepoint that coincides with the onset of intracellular viral RNA synthesis, as expected for a molecule that specifically targets the viral helicase. CONCLUSIONS: The well-tolerated drug ivermectin may hold great potential for treatment of YFV infections. Furthermore, structure-based optimization may result in analogues exerting potent activity against flaviviruses other than YFV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An approach to computing electrostatic charges for molecules
Singh, U. C., & Kollman, P. A. (1984) · Journal of Computational Chemistry · doi:10.1002/jcc.540050204 · Cited by 3,428
Goodford, P. J. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00145a002 · Cited by 2,634
A structural perspective of the flavivirus life cycle
Mukhopadhyay, S., Kuhn, R. J., & Rossmann, M. G. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1067 · Cited by 1,292
Gould, E., & Solomon, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60238-x · Cited by 818
Velankar, S. S., Soultanas, P., Dillingham, M. S., Subramanya, H. S., & Wigley, D. B. (1999) · Cell · doi:10.1016/s0092-8674(00)80716-3 · Cited by 784
Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans
Cully, D. F., Vassilatis, D. K., Liu, K. K., Paress, P. S., Van der Ploeg, L. H. T., Schaeffer, J. M., & Arena, J. P. (1994) · Nature · doi:10.1038/371707a0 · Cited by 756
A new model for calculating atomic charges in molecules
Gasteiger, J., & Marsili, M. (1978) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)94977-9 · Cited by 611
Helicase structure and mechanism
Caruthers, J. M., & McKay, D. B. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00298-1 · Cited by 566
Monath, T. P. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00016-0 · Cited by 534
An adenosine nucleoside inhibitor of dengue virus
Yin, Z., Chen, Y.-L., Schul, W., Wang, Q.-Y., Gu, F., Duraiswamy, J., Kondreddi, R. R., Niyomrattanakit, P., Lakshminarayana, S. B., Goh, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907010106 · Cited by 390
Yellow Fever: A Disease that Has Yet to be Conquered
Barrett, A. D. T., & Higgs, S. (2007) · Annual Review of Entomology · doi:10.1146/annurev.ento.52.110405.091454 · Cited by 387
Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site
Vicens, Q., & Westhof, E. (2001) · Structure · doi:10.1016/s0969-2126(01)00629-3 · Cited by 373
Ivermectin: 25 years and still going strong
Õmura, S. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.08.023 · Cited by 338
Ivermectin 20 years on: maturation of a wonder drug
GEARY, T. (2005) · Trends in Parasitology · doi:10.1016/j.pt.2005.08.014 · Cited by 303
Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein
Luo, D., Xu, T., Watson, R. P., Scherer‐Becker, D., Sampath, A., Jahnke, W., Yeong, S. S., Wang, C. H., Lim, S. P., Strongin, A., et al. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.232 · Cited by 271
Selective inhibitors of picornavirus replication
De Palma, A. M., Vliegen, I., De Clercq, E., & Neyts, J. (2008) · Medicinal Research Reviews · doi:10.1002/med.20125 · Cited by 259
Self-citationChapter 1 The History and Evolution of Human Dengue Emergence
Vasilakis, N., & Weaver, S. C. (2008) · Advances in Virus Research · doi:10.1016/s0065-3527(08)00401-6 · Cited by 225
Chu, P., & Westaway, E. G. (1985) · Virology · doi:10.1016/0042-6822(85)90446-5 · Cited by 176
The Relationships between West Nile and Kunjin Viruses
Scherret, J., Poidinger, M., Mackenzie, J. S., BROOM, A. K., Deubel, V., Lipkin, W. I., Briese, T., Gould, E. A., & Hall, R. A. (2001) · Emerging infectious diseases · doi:10.3201/eid0704.017418 · Cited by 176
West Nile Virus in the Americas
Petersen, L. R., & Hayes, E. B. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2008.07.004 · Cited by 158
A two-step chirality transfer from (−)-endo- to (−)-exo-tricyclo[5.2.1.026]deca-4,8-dien-3-one
Dols, P. P. M. A., Klunder, A. J. H., & Zwanenburg, B. (1993) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)93412-9 · Cited by 110
Zhang, N., Chen, H., Koch, V., SCHMITZ, H. E., Liao, C., Bretner, M., Bhadti, V. S., Fattom, A., Naso, R. B., Hosmane, R. S., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030842j · Cited by 87
Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987–2007
Guzmán, M. G., & Kourí, G. (2008) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2008.03.001 · Cited by 78
Zioudrou, C., Moustakali‐Mavridis, I., CHRYSOCHOU, P., et al. (1978) · Tetrahedron · doi:10.1016/0040-4020(78)87014-8 · Cited by 20
(1998) · doi:10.1002/(sici)1096-987x(19981115)19:14<1639::aid-jcc10>3.0.co;2-b
Cited by
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Zika, Chikungunya, and Other Emerging Vector-Borne Viral Diseases
Weaver, S. C., Charlier, C., Vasilakis, N., & Lecuit, M. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050715-105122 · Cited by 501
A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection
Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., Soto-Acosta, R., Galarza-Muñoz, G., McGrath, E. L., Urrabaz-Garza, R., Gao, J., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.07.004 · Cited by 497
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Heidary, F., & Gharebaghi, R. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0336-z · Cited by 435
Metadata
- Authors
- Mastrangelo, E., Pezzullo, M., De Burghgraeve, T., Kaptein, S., Pastorino, B., Dallmeier, K., de Lamballerie, X., Neyts, J., Hanson, A. M., Frick, D. N., Bolognesi, M., & Milani, M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-04-25
- Volume
- 67
- Issue
- 8
- Pages
- 1884-1894
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2165157662
- Cited by
- 414
- References
- 25
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.